Journal
FUTURE MEDICINAL CHEMISTRY
Volume 7, Issue 9, Pages 1149-1171Publisher
FUTURE SCI LTD
DOI: 10.4155/FMC.15.53
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81273375]
Ask authors/readers for more resources
This review covers the recent advances in the development of small RGD (Arg-Gly-Asp sequence) containing peptides and their mimetics as potential antithrombotic agents. Glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists include monoclonal antibodies, RGD peptides, peptide hybrids and nonpeptide mimetics. The current trend in the development of nonpeptide mimetics is clearly directed toward orally active and safe antithrombotic drug candidates. But several nonpeptide mimetics, being evaluated for their oral activity in human clinical trials, are currently not approved for clinical use due to poor safety profile. It is expected that newer and more effective nonpeptide mimetics will be developed in the near future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available